精准肿瘤学的创新：基于生物标志物的方法以强化癌症治疗
Innovations in Precision Oncology: Biomarker-Driven Approaches for Enhanced Cancer Therapy.
作者信息
Kargbo Robert B
机构信息
Usona Institute, Fitchburg, Wisconsin 53711-5300, United States.
出版信息
ACS Med Chem Lett. 2024 Jan 25;15(2):169-170. doi: 10.1021/acsmedchemlett.4c00002. eCollection 2024 Feb 8.
Precision oncology is revolutionized by targeted therapies like talazoparib, a PARP inhibitor, leveraging advanced understanding of DNA repair mechanisms such as ribonucleotide excision repair and homologous recombination repair. CRISPR-Cas technology has been pivotal in unraveling these pathways, facilitating personalized treatment strategies. The identification of genomic loss of heterozygosity as a biomarker targets HRR-deficient cancers, enhancing talazoparib's efficacy. These breakthroughs represent a significant advancement in precision medicine, offering more effective, individualized cancer therapies.
精准肿瘤学因像他拉唑帕尼这样的靶向疗法而发生了变革，他拉唑帕尼是一种聚（ADP-核糖）聚合酶（PARP）抑制剂，它利用了对核糖核苷酸切除修复和同源重组修复等DNA修复机制的深入理解。CRISPR-Cas技术在揭示这些途径方面发挥了关键作用，推动了个性化治疗策略的发展。将基因组杂合性缺失鉴定为生物标志物，可针对同源重组修复缺陷的癌症，提高他拉唑帕尼的疗效。这些突破代表了精准医学的重大进展，提供了更有效、个性化的癌症治疗方法。
Zotero 插件